Home/Filings/4/0001628280-22-004499
4//SEC Filing

Taveras Arthur 4

Accession 0001628280-22-004499

CIK 0001501697other

Filed

Feb 28, 7:00 PM ET

Accepted

Mar 1, 4:09 PM ET

Size

5.4 KB

Accession

0001628280-22-004499

Insider Transaction Report

Form 4
Period: 2022-03-01
Taveras Arthur
Chief Scientific Officer
Transactions
  • Award

    Common Stock

    2022-03-01+97,000104,107 total
Footnotes (2)
  • [F1]Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.
  • [F2]Of the shares of common stock reported, 102,357 shares represent unvested restricted stock units.

Issuer

X4 Pharmaceuticals, Inc

CIK 0001501697

Entity typeother

Related Parties

1
  • filerCIK 0001830901

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 4:09 PM ET
Size
5.4 KB